Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Neuraxpharm’s New Belgian Division Advances European Expansion Strategy

New Unit Plans To Launch Products From Recent Sanofi Acquisition

Executive Summary

Neuraxpharm continues its European expansion with a new Brussels-based Belgian unit to be headed by country manager Pierre-Hervé Brun. The announcement adds to the more than 20 European countries where the company is recognized and established. 

You may also be interested in...



Neuraxpharm Expands European Reach With Dutch Operation

Neuraxpharm has made its latest move into a new European market, this time opening up a new unit in the Netherlands that will be led by the firm’s German head Philipp Pohoralek as country manager.

Deal Watch: BMS Backs Out Of UniQure Gene Therapy Collaboration

The gene therapy firm announced that Bristol terminated a collaboration started in 2015. Nona follows its recent alliance with Moderna with a second collaboration, this time with Dragonfly.

Panaxia And Neuraxpharm Sign To Sell Medical Cannabis In The Czech Republic And Switzerland

Panaxia and Neuraxpharm have added the Czech Republic and Switzerland to their growing list of European markets for medical cannabis. Both countries have passed recent legislation to stimulate prescriptions of cannabis products.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152470

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel